- Home
- SABA vs SWKH Comparison
SABA vs SWKH Comparison
Compare SABA & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SABA | SWKH |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Diversified Financial Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 205.9M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SABA | SWKH |
|---|---|---|
| Price | $8.14 | $16.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 147.3K | 5.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.72 | $13.00 |
| 52 Week High | $9.46 | $18.66 |
Technical Indicators
Market Signals| Indicator | SABA | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | N/A |
| Support Level | $7.96 | N/A |
| Resistance Level | $8.87 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 63.16 | 0.00 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.